eMedicine Specialties > Physical Medicine and Rehabilitation > Lower Limb Musculoskeletal Conditions

Calcaneal Bursitis: Treatment & Medication

Author: Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain (Tailbone Pain, Coccydynia) Service, University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Coauthor(s): Todd P Stitik, MD, Professor, Department of Physical Medicine and Rehabilitation, Acting Director of Sports Medicine, UMDNJ-New Jersey School of Medicine; Lead Physician, Practice Medical Director of University Hospital PM & R Clinic
Contributor Information and Disclosures

Updated: May 4, 2008

Treatment

Rehabilitation Program

Physical Therapy

Gradually progressive stretching of the Achilles tendon may help to relieve impingement on the subtendinous calcaneal bursa. Stretching of the Achilles tendon can be performed by having the patient place the affected foot flat on the floor and lean forward toward the wall until a gentle stretch is felt in the ipsilateral Achilles tendon. The stretch is maintained for 20-60 seconds and then is relaxed. This technique is demonstrated in Images 1-2. Another technique, a more advanced stretch that isolates the Achilles tendon, is shown in Images 3-4.

To maximize the benefit of the stretching program, the patient should repeat the exercise for multiple stretches per set, multiple times per day. Ballistic (ie, abrupt, jerking) stretches should be avoided in order to prevent clinical exacerbation.

The patient should be instructed to ice the posterior heel and ankle in order to reduce inflammation and pain. Icing can be performed for 15-20 minutes at a time, several times a day, during the acute period, which may last for several days. Some clinicians also advocate the use of contrast baths, ultrasound or phonophoresis, iontophoresis, or electrical stimulation for treatment of calcaneal bursitis.

If the patient's activity level needs to be decreased as a result of this condition, alternative means of maintaining strength and cardiovascular fitness (eg, swimming, water aerobics) should be suggested.

Medical Issues/Complications

  • Addressing footwear
    • Changing footwear may be the most important form of treatment for calcaneal bursitis. The use of an open-backed shoe may relieve pressure on the affected region.
    • Individuals whose symptoms have been precipitated by a dramatic footwear change, specifically, a switch from high-heeled shoes to flat shoes (or vice versa), may need to temporarily use footwear with a medium heel height.
    • Athletes should be encouraged to change running shoes on a regular basis, because the shoes' fit, as well as the support the shoes provide, may change over the course of hundreds of miles of use.
  • Further modification of shoes
    • A portion of the heel counter can be cut away and replaced with a soft leather insert to decrease friction at the site where the heel counter meets the skin.
    • Shoes without laces (eg, slip-on shoes, sandals) inherently fit closely onto the heel and should be avoided.
    • Inserting a heel cup into the shoe may help to raise the inflamed region slightly above the restricting heel counter. If this approach is implemented, a heel cup should also be placed into the other shoe to avoid introducing a leg-length discrepancy.
  • Immobilization
    • The initial accommodation of the bursitis by the introduction of rest or of a decrease in or modification of activity may suffice to reverse the bursitis and its symptoms.
    • If the symptoms are resistant to the above treatments, immobilization in a cast for 4-6 weeks should be considered.
  • Complications from calcaneal bursitis or its treatment
    • Progressive posterior heel and ankle pain
    • Rupture of the Achilles tendon, either secondary to chronic local inflammation/degeneration or as a result of corticosteroid injection(s)
    • Some clinicians advocate the use of corticosteroid injection(s) into the affected bursa, being careful to avoid injection within the Achilles tendon.12 Because of the close proximity of the Achilles tendon to the bursae, such injections should be considered only in severe, recalcitrant cases. The authors of this article generally recommend against corticosteroid injection in the vicinity of the Achilles tendon because of the potential risk of tendon rupture. However, prospective, randomized studies have not been performed to establish whether steroid injections cause such tendon ruptures. Instead, the association between steroid injections and subsequent tendon ruptures is mostly based on retrospective case reports. Potentially, those cases that were more likely to go on to rupture were also more likely to have a severe presentation that prompted the steroid injections.
    • One case report demonstrated that subtendinous calcaneal bursitis can be not only diagnosed but also treated with ultrasonography. Ultrasonographic guidance can be used to inject the subtendinous calcaneal bursa with a commendation of local anesthetic (eg, lidocaine, giving relief within minutes and lasting several hours) combined with corticosteroid (eg, Kenalog, producing an anti-inflammatory effect within 24-48 h and providing relief for weeks to months). The authors feel that using ultrasonographic guidance can help to ensure reliable, accurate delivery of medication into the bursa while avoiding intratendinous injection.11

Surgical Intervention

For patients who have persistent or progressive symptoms despite rigorous nonsurgical treatment, the following surgical interventions are options:

  • Resection of Haglund deformity, removing the calcaneal superoposterior prominence (ostectomy)
  • Excision of the painful bursa or bursae
  • Debridement of the Achilles insertion
  • In cases of Achilles tendon rupture or avulsion, surgical re-anastomosis is indicated.
  • Outpatient endoscopic removal of the inflamed bursal tissue and resection of the prominent bone.13

Consultations

Patients requiring surgical intervention should be referred for surgical consultation to an orthopedic surgeon who is experienced in foot and ankle surgery.

Other Treatment

As discussed above, corticosteroid injection in this region is not recommended because of the potential risk of rupturing the Achilles tendon.

Medication

For this musculoskeletal condition, medications are used primarily to decrease pain and inflammation. Thus, the most commonly used medications are oral nonsteroidal anti-inflammatory drugs (NSAIDs), which are employed in conjunction with the rest of the rehabilitation plan.14

Nonsteroidal anti-inflammatory drugs

Oral NSAIDs can help to decrease pain and inflammation. Various oral NSAIDs can be used, with the choice of drug being largely a matter of convenience (how frequently doses must be taken to achieve adequate analgesic and anti-inflammatory effects) and cost.


Ibuprofen (Motrin, Advil, Nuprin, Rufen)

DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. Various doses are available with and without a prescription.

Adult

200-800 mg PO tid/qid

Pediatric

<6 months: Not established
6 months to 12 years: 4-10 mg/kg/dose PO tid/qid
>12 years: Administer as in adults

Co-administration with aspirin increases risk of inducing serious, NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when phenytoin is administered concurrently

Documented hypersensitivity, peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, patients with high risk of bleeding

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Naproxen (Naprelan, Naprosyn, Aleve, Anaprox)

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis.

Adult

500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Co-administration with aspirin increases risk of inducing serious, NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when phenytoin is administered concurrently

Documented hypersensitivity; peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with pre-existing renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely and is transient, usually clearing up during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug


Ketoprofen (Actron, Orudis, Oruvail)

For relief of mild to moderate pain and inflammation.
Small dosages are initially indicated in small and elderly patients and in persons with renal or liver disease. Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response.

Adult

25-50 mg PO q6-8h prn; not to exceed 300 mg/d

Pediatric

<3 months: Not established
3 months to 12 years: 0.1-1 mg/kg PO q6-8h
>12 years: Administer as in adults

Co-administration with aspirin increases risk of inducing serious, NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when phenytoin is administered concurrently

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Flurbiprofen (Ansaid)

May inhibit cyclo-oxygenase enzyme, which in turn inhibits prostaglandin biosynthesis. These effects may result in analgesic, antipyretic, and anti-inflammatory activities.

Adult

200-300 mg/d PO divided bid/qid

Pediatric

Not established

Co-administration with aspirin increases risk of inducing serious, NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when phenytoin is administered concurrently

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with pre-existing renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely and is transient, usually clearing up during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug

More on Calcaneal Bursitis

Overview: Calcaneal Bursitis
Differential Diagnoses & Workup: Calcaneal Bursitis
Treatment & Medication: Calcaneal Bursitis
Follow-up: Calcaneal Bursitis
Multimedia: Calcaneal Bursitis
References

References

  1. Brinker MR, Miller MD. The adult foot. In: Fundamentals of Orthopaedics. Philadelphia, Pa: WB Saunders; 1999:342-63.

  2. Foot and ankle. In: Snider RK, ed. Essentials of Musculoskeletal Care. Rosemont, Ill: American Academy of Orthopaedic Surgeons; 1997:366-489.

  3. McGee DJ. Lower leg, ankle, and foot. In: Orthopedic Physical Assessment. 2nd ed. Philadelphia, Pa: WB Saunders; 1992:448-515.

  4. Kachlik D, Baca V, Cepelik M, et al. Clinical anatomy of the retrocalcaneal bursa. Surg Radiol Anat. Mar 11 2008;[Medline].

  5. Teebagy AK. Leg and ankle. In: Steinberg GG, Akins CM, Baran DT, eds. Orthopaedics in Primary Care. 3rd ed. Baltimore, Md: Lippincott Williams & Wilkins; 1999:241-67.

  6. Young JL, Olsen NK, Press JM. Musculoskeletal disorders of the lower limbs. In: Braddom RL, ed. Physical Medicine and Rehabilitation. Philadelphia, Pa: WB Saunders; 1996:783-812.

  7. Aldridge T. Diagnosing heel pain in adults. Am Fam Physician. Jul 15 2004;70(2):332-8. [Medline][Full Text].

  8. Eshed I, Althoff CE, Feist E, et al. Magnetic resonance imaging of hindfoot involvement in patients with spondyloarthritides: comparison of low-field and high-field strength units. Eur J Radiol. Jan 2008;65(1):140-7. [Medline].

  9. Erdem CZ, Tekin NS, Sarikaya S, et al. MR imaging features of foot involvement in patients with psoriasis. Eur J Radiol. Nov 8 2007;[Medline].

  10. Reiter M, Ulreich N, Dirisamer A, et al. [Extended field-of-view sonography in Achilles tendon disease: a comparison with MR imaging]. Rofo. May 2004;176(5):704-8. [Medline].

  11. Sofka CM, Adler RS, Positano R, et al. Haglund's syndrome: diagnosis and treatment using sonography. HSS J. Feb 2006;2(1):27-9.

  12. Olsen NK, Press JM, Young JL. Bursal injections. In: Lennard TA, ed. Physiatric Procedures in Clinical Practice. Philadelphia, Pa: Hanley & Belfus; 1995:36-43.

  13. Ortmann FW, McBryde AM. Endoscopic bony and soft-tissue decompression of the retrocalcaneal space for the treatment of Haglund deformity and retrocalcaneal bursitis. Foot Ankle Int. Feb 2007;28(2):149-53. [Medline].

  14. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: Green SM, ed. Tarascon Pocket Pharmacopoeia 2000. Loma Linda, Calif: Tarascon Pub; 2000:11-2.

Further Reading

Keywords

calcaneal bursitis, bursitis of the subtendinous or subcutaneous bursa of the calcaneal (Achilles) tendon, bursitis of the subtendinous or subcutaneous calcaneal bursa, bursitis of the subtendinous or subcutaneous retrocalcaneal bursa, exostosis, Haglund deformity, prominence of the posterior superior calcaneus, retrocalcaneal bursitis, pump bump

Contributor Information and Disclosures

Author

Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain (Tailbone Pain, Coccydynia) Service, University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Patrick M Foye, MD, FAAPMR, FAAEM is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society
Disclosure: Nothing to disclose.

Coauthor(s)

Todd P Stitik, MD, Professor, Department of Physical Medicine and Rehabilitation, Acting Director of Sports Medicine, UMDNJ-New Jersey School of Medicine; Lead Physician, Practice Medical Director of University Hospital PM & R Clinic
Todd P Stitik, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists, Phi Beta Kappa, and Physiatric Association of Spine, Sports and Occupational Rehabilitation
Disclosure: Nothing to disclose.

Medical Editor

Daniel D Scott, MD, MA, BS, Associate Professor, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver and Health Sciences Center
Daniel D Scott, MD, MA, BS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, National Multiple Sclerosis Society, and Physiatric Association of Spine, Sports and Occupational Rehabilitation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Michael T Andary, MD, MS, Residency Program Director, Professor, Department of Physical Medicine and Rehabilitation, Michigan State University College of Osteopathic Medicine
Michael T Andary, MD, MS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, and Association of Academic Physiatrists
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center
Disclosure: Nothing to disclose.

Chief Editor

Consuelo T Lorenzo, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Alegent Health Care, Immanuel Rehabilitation Center
Consuelo T Lorenzo, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.